Literature DB >> 2741752

Malignant hyperthermia in an office surgery suite: a case report.

I M Turpin1, J Manino.   

Abstract

Malignant hyperthermia is a threat to the life of the surgical patient. It is a pharmacogenic disease that is brought on by contact with certain drugs and is manifest by a hypermetabolic crisis with tachycardia, ventricular ectopy, metabolic acidosis, and a rapid rise in body temperature. Muscle rigidity may or may not be present. Thanks to a reliable porcine animal model of malignant hyperthermia, dantrolene sodium has been found to be effective in the prevention and treatment of malignant hyperthermia. In this article a case report of malignant hyperthermia occurring in an office surgery suite is presented. The patient was 37 years old and underwent a routine septorhinoplasty under general anesthesia. The operation was complicated by ventricular ectopy, rapid rise in body temperature, and muscle rigidity at the end of the case. The malignant hyperthermia aborted spontaneously after 30 minutes; dantrolene was not given.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2741752     DOI: 10.1007/bf01571480

Source DB:  PubMed          Journal:  Aesthetic Plast Surg        ISSN: 0364-216X            Impact factor:   2.326


  10 in total

Review 1.  Epidemiology and inheritance of malignant hyperthermia.

Authors:  W Kalow; B A Britt; F Y Chan
Journal:  Int Anesthesiol Clin       Date:  1979

2.  Dantrolene dose response in awake man: implications for management of malignant hyperthermia.

Authors:  E H Flewellen; T E Nelson; W P Jones; J F Arens; D L Wagner
Journal:  Anesthesiology       Date:  1983-10       Impact factor: 7.892

3.  Malignant hyperthermia after oral and intravenous pretreatment with dantrolene in a patient susceptible to malignant hyperthermia.

Authors:  G Ruhland; A J Hinkle
Journal:  Anesthesiology       Date:  1984-02       Impact factor: 7.892

4.  Prophylactic and therapeutic doses of dantrolene for malignant hyperthermia.

Authors:  E H Flewellen; T E Nelson
Journal:  Anesthesiology       Date:  1984-10       Impact factor: 7.892

5.  Malignant hyperthermia following preoperative oral administration of dantrolene.

Authors:  D C Fitzgibbons
Journal:  Anesthesiology       Date:  1981-01       Impact factor: 7.892

6.  Dantrolene--in vitro studies in malignant hyperthermia susceptible (MHS) and normal skeletal muscle.

Authors:  B A Britt; E Scott; W Frodis; M J Clements; L Endrenyi
Journal:  Can Anaesth Soc J       Date:  1984-03

7.  Malignant hyperthermia susceptibility--successful management with a "stressfree" technique.

Authors:  J P Jantzen; K Erdmann; P P Kleemann
Journal:  Acta Anaesthesiol Belg       Date:  1987

Review 8.  Malignant hyperthermia in the head and neck surgery patient: an update and review.

Authors:  R A Pollock; B A Britt
Journal:  Laryngoscope       Date:  1983-03       Impact factor: 3.325

Review 9.  Malignant hyperthermia.

Authors:  M Marmor
Journal:  Surv Ophthalmol       Date:  1983 Sep-Oct       Impact factor: 6.048

Review 10.  Malignant hyperthermia.

Authors:  G A Gronert
Journal:  Anesthesiology       Date:  1980-11       Impact factor: 7.892

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.